Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell vaccine (T24 tumor antigen)
- Development stage
- Preclinical
- Lead developer
- Wang et al.
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
An experimental autologous dendritic cell (DC) vaccine designed for the treatment of bladder cancer. The vaccine is produced by isolating human peripheral blood leukocytes, differentiating them into dendritic cells, and loading them with whole tumor antigens derived from the T24 bladder cancer cell line. In preclinical studies using humanized mouse models (hu-PBL-SCID), the vaccine demonstrated the ability to inhibit tumor growth and downregulate matrix metalloproteinase-7 (MMP-7) expression, suggesting its potential as a personalized immunotherapy strategy. This vaccine represents a research-stage compound evaluated for its ability to generate a targeted anti-tumor immune response.
- Other names
- T24-loaded dendritic cell vaccineT-24-loaded dendritic cell vaccineT 24-loaded dendritic cell vaccineautologous DC vaccine for bladder cancerautologous dendritic cell vaccine-Tumor-associated antigens-Dendritic cell therapy-Vaccine-Bladder Cancer
02
Targets
Neoantigen (Patient-specific tumor-specific neoantigen)
Beyond the preview
Go deeper on autologous dendritic cell vaccine (T24 tumor antigen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell vaccine (T24 tumor antigen).